NCT00335348View on ClinicalTrials.gov

Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse

PHASE2CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Multiple Myeloma
Interventions
DRUG

Bortezomib

Induction- 1.3mg/m2 IV days 1,4,8,11 every 3 weeks up to 8 cycles Consolidation- 1.3mg/m2 IV days 1,8,15,22 every 5 weeks up to 3 cycles Maintenance- 1.3mg/m2 IV days 1,15 every 4 weeks

DRUG

Dexamethasone

Induction- 20mg orally days 1,2,4,5,8,9,11,12 every 3 weeks up to 8 cycles Consolidation- 20mg orally days 1,2,8,9,15,16,22,23 every 5 weeks up to 3 cycles Maintenance- 20mg orally days 1,2,15,16 every 4 weeks

Trial Locations (1)

8006

Peter MacCallum Cancer Centre, Melbourne

All Listed Sponsors
collaborator

Janssen-Cilag Ltd.

INDUSTRY

lead

Peter MacCallum Cancer Centre, Australia

OTHER

NCT00335348 - Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse | Biotech Hunter | Biotech Hunter